Clinical Trials Logo

Pulmonary Heart Disease clinical trials

View clinical trials related to Pulmonary Heart Disease.

Filter by:

NCT ID: NCT06379711 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Cardiopulmonary Changes Following Spinal Cord Stimulation in Individuals With Spinal Cord Injury

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to examine the mechanisms of transcutaneous spinal cord stimulation (tSCS) for improving cardiovascular and pulmonary function in individuals with chronic motor-complete spinal cord injury (SCI) by measuring vascular related endothelial biomarkers, plasma catecholamines, and respiratory parameters.

NCT ID: NCT05776264 Completed - Clinical trials for Chronic Lung Disease

Exercise Strategies to Motivate and Relieve Stress

Start date: March 29, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate exercise strategies that motivate and relive stress in adults with cardiopulomnary conditions. The goals of this study are as follows: - To explore the feasibility (how easily it can be done) of using self-selected music during exercise training for adults with cardiopulmonary conditions. - To assess patient satisfaction of self-selected music with exercise for adults with cardiopulmonary conditions. - To explore the immediate effects of self-selected music on mood and symptoms (shortness of breath and fatigue) compared with listening to a podcast during their exercise training session Participants will: - Select 5-7 songs and 1 podcast to listen to during their treatment session - Walk on the treadmill while either listening to a podcast or music - Fill out surveys about their mood, symptoms (shortness of breath and fatigue), music/podcast, and exercise

NCT ID: NCT05733767 Recruiting - Smoking Cessation Clinical Trials

Smoking Cessation Pharmacotherapy-Nurse Practitioner Led Tobacco Treatment Team Study

STOP-NPT3
Start date: November 3, 2022
Phase: Phase 2
Study type: Interventional

Tobacco use remains the leading cause of death in the United States and contributes to more than 7 million hospitalizations annually. Being admitted to the hospital offers the perfect opportunity to support smoking cessation. Patients are motivated to quit because of their current illness and societal guidelines recommend clinicians should counsel patients and prescribe smoking cessation pharmacotherapy (SCP) to virtually all smokers. However, only 22% of patients are prescribed SCP while hospitalized, and only 1% are prescribed medications compatible with current guidelines. This failure is part of the reason 70-80% of hospitalized smokers eventually relapse. The relapse typically occurs within a few days of hospital discharge - well before outpatient follow-up can occur. The investigators aim to improve smoking cessation treatment and guideline adherence by utilizing the opportunity that hospitalization provides. The investigators have created a tobacco treatment team (T3) to overcome physicians' and patients' low use of current guideline smoking cessation medications. The team members are trained in tobacco treatment and will be led by a nurse practitioner (NPT3). The team will work together and 1) prescribe individually tailored and guideline-concordant SCP; 2) counsel and motivate patients to use SCP properly; and 3) manage a mobile phone-based text-messaging system to keep patients motivated and adherent to SCP. Our preliminary data suggest that such an approach is workable and acceptable to patients, physicians, and hospital administrators. The investigators will recruit 424 patients in the hospital who smoke with cardiopulmonary disease. These patients will be randomized to receive either usual care or personalized care with the NPT3 team. The investigators will compare rates of guideline-concordant SCP use at 1 week and exhaled carbon monoxide (eCO) verified smoking cessation at 6 months between patients randomized to the NPT3 team vs. usual care. The investigators will also measure the project's economic value from a hospital and payer perspective. Understanding the economic value will better inform hospital and insurance policies and sustainability. Finally, acceptability, generalizability, and sustainability measures will be assessed through qualitative interviews with patients, providers, and hospital leadership.

NCT ID: NCT05629832 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Transpulmonary Pressure in Right Ventricle Protection of ARDS

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

To compare the effect between mechanical ventilation strategy guided by transpulmonary pressure and tranditional lung protective ventilation strategy in acute respiratory distress syndrome for right ventricle protection.

NCT ID: NCT05584722 Recruiting - Clinical trials for Idiopathic Pulmonary Arterial Hypertension

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

RARE-PAH
Start date: November 1, 2022
Phase:
Study type: Observational

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify new therapeutic targets. Funding Source - FDA OOPD

NCT ID: NCT05445492 Active, not recruiting - Clinical trials for Cardiopulmonary Disease

Respiration Validation for CPM Device

Start date: June 22, 2022
Phase: Phase 2
Study type: Interventional

This study is designed to be a clinical validation study to ready the CPM System for FDA 510(k) submission. This study will be conducted as a prospective non-randomized. The study is non-significant risk since the CPM Device is noninterventional and noninvasive. The study is primarily designed to validate the accuracy of the respiration rate and the changes in relative tidal volume. All participants will be fitted with both the CPM Device as well as reference devices (capnography and ECG). Participants will be randomized between 4 procedures (A-D) which will determine the order of 10 exercises. Each exercise has about 2 minutes of device recording and two minutes of rest. Each exercise contains two positions: sitting up for one minute and lying down for one minute. For some exercises, the participant will be instructed to breathe at a certain rate (assisted by a metronome). For other exercises, the participants will breathe at a normal rate but change how deep the are breathing. For the last, all capnography reference devices will be removed, and an ECG reference device will be placed. After exercise 18, the participant will have all devices removed and the study visit will terminate. The participant will receive a safety follow-up call about 1 week after their visit.

NCT ID: NCT05319236 Completed - Clinical trials for Cardiovascular Diseases

Clinical Use Cases Assessment of the Gabi System in Young Children With Underlying Medical Conditions (BRIDGE Study)

BRIDGE
Start date: February 16, 2022
Phase: N/A
Study type: Interventional

Subjects will use the Gabi system on a daily basis for 3 months, each time the subject is resting or asleep. The Gabi system will recording the SpO2, pulse rate, respiratory rate and movements of the subject. The objective of this study is to perform a first assessment of the range of most potentially clinically relevant indications for use of the Gabi system for children < 6 years old with underlying medical conditions. This is performed by asking HCPs to review the data measured by the Gabi system after taking a medical decision independently from the Gabi data and to assess the potential clinical utility of the Gabi system. The usability of the system will also be assessed throughout questionnaires filled out by the HCPs and by the caregivers. *During this study, the data collected by the Gabi system are not intended to be used by caregivers or HCPs to take any (medical) decisions.

NCT ID: NCT05172388 Completed - Clinical trials for Cardiopulmonary Diseases

Indoor Air Filtration and Young Adults Health Study

Start date: December 29, 2021
Phase: N/A
Study type: Interventional

This study aims to explore the cardiopulmonary health effects of indoor air purification and other indoor environmental conditions among young healthy college students in Beijing, China.

NCT ID: NCT05079724 Not yet recruiting - Heart Diseases Clinical Trials

Acute Kidney Injury After Cardiac Surgery

Start date: November 1, 2021
Phase:
Study type: Observational

The study aims to identify the Following: - 1. incidence and mortality of cardiac Surgery associated -AKI based on the new consensus diagnostic systems of KDIGO (Kidney Disease Improving Global Outcomes). 2. use of biomarkers for the early detection of clinical and subclinical cardiac Surgery associated-AKI. 3. risk factors and prediction models of cardiac Surgery associated-AKI. 4. optimal cardiac surgical procedures including conventional versus minimally invasive approaches, on-pump versus off-pump, and optimal management of cardiac surgical support including duration of CPB, perfusion pressure, hemodilution, and hypothermia during CPB. 5. controversial pharmacologic therapies for the prevention and treatment of cardiac Surgery associated-AKI including statins, sodium bicarbonate, and N-acetylcysteine (NAC).

NCT ID: NCT04939220 Not yet recruiting - Clinical trials for Cardiopulmonary Disease

SGA for TEE: Safe Alternative to Deep Sedation for Patients With High-risk Cardiopulmonary Disease.

SGA-TEE
Start date: February 2024
Phase: N/A
Study type: Interventional

Increasingly, transesophageal echos (TEEs) are being done on high risk patients. A TEE is a short procedure done with deep sedation, but poses an increased risk of apnea/ hypoxemia in those with pulmonary disease. It is desirable to avoid intubation, which adds risk. Use of supraglottic airway (SGA) may offer an alternative. The investigators hypothesize that TEEs can be done successfully with an SGA in place. The investigators propose a prospective RCT to compare TEE exams done with deep sedation to those done with an SGA.